Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

Autor: Paz-Ares LG; Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Complutense University and Ciberonc, Madrid, Spain., Juan-Vidal O; Hospital Universitari i Politécnic La Fe de Valencia, Valencia, Spain., Mountzios GS; Henry Dunant Hospital Center, Athens, Greece., Felip E; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain., Reinmuth N; Asklepios Lung Clinic, German Center for Lung Research (DZL), Munich-Gauting, Germany., de Marinis F; European Institute of Oncology IRCCS, Milan, Italy., Girard N; Institut du Thorax Curie Montsouris, Institut Curie, Paris, France., Patel VM; Florida Cancer Specialists and Research Institute, Ocala, FL., Takahama T; Kindai University, Osaka, Japan., Owen SP; McGill University Health Centre, Montreal, QC, Canada., Reznick DM; Rocky Mountain Cancer Center, Aurora, CO., Badin FB; Baptist Health Medical Group, Lexington, KY., Cicin I; Istinye University, Medical Center, Istanbul, Turkey., Mekan S; Gilead Sciences, Inc, Foster City, CA., Patel R; Gilead Sciences, Inc, Foster City, CA., Zhang E; Gilead Sciences, Inc, Foster City, CA., Karumanchi D; Gilead Sciences, Inc, Foster City, CA., Garassino MC; University of Chicago Comprehensive Cancer Center, Chicago, IL.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Aug 20; Vol. 42 (24), pp. 2860-2872. Date of Electronic Publication: 2024 May 31.

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

Autor: Levy B; Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Washington, DC. Electronic address: blevy11@jhmi.edu., Paz-Ares L; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Bennouna J; Department of Pneumology, Thoracic Oncology, University Hospital-Nantes, Nantes, France., Felip E; Medical Oncology Department, Vall d'Hebron Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain., Abreu DR; Department of Medical Oncology, Gran Canaria University Hospital, Las Palmas de Gran Canaria, Spain., Isla D; Department of Medical Oncology, University Hospital Lozano Blesa, Zaragoza, Spain., Barlesi F; Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France., Molinier O; Pneumology, Centre Hospitalier Le Mans, Le Mans, France., Madelaine J; Pulmonology Department, Caen University Hospital, Caen, France., Audigier-Valette C; Service de Pneumologie, Centre Hospitalier Sainte Musse, Toulon, France., Kim SW; Asan Medical Center, Seoul, South Korea., Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Ozguroglu M; Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey., Erman M; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Badin FB; Hematology and Oncology, Baptist Health Medical Group, Lexington, KY., Mekhail TM; Florida Hospital Cancer Institute, Orlando, FL., Scheff R; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell College of Medicine, New York, NY., Chisamore MJ; Merck & Co, Inc, Rahway, NJ., Sadrolhefazi B; Boehringer Ingelheim Canada Ltd, Burlington, Ontario, Canada., Riess JW; UC Davis Comprehensive Cancer Center, Sacramento, CA.

Publikováno v: Clinical lung cancer [Clin Lung Cancer] 2019 May; Vol. 20 (3), pp. e407-e412. Date of Electronic Publication: 2019 Jan 04.